$8.11
1.44% today
NYSE, Feb 05, 04:16 pm CET
ISIN
US03168L1052
Symbol
AMRX
Sector
Industry

Amneal Pharmaceuticals, Inc. Class A Stock price

$7.99
+0.22 2.83% 1M
+1.29 19.25% 6M
+0.07 0.88% YTD
+2.47 44.75% 1Y
+3.39 73.70% 3Y
+3.36 72.57% 5Y
-7.02 46.77% 10Y
NYSE, Closing price Tue, Feb 04 2025
-0.19 2.32%
ISIN
US03168L1052
Symbol
AMRX
Sector
Industry

Key metrics

Market capitalization $2.48b
Enterprise Value $5.10b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 50.36
EV/Sales (TTM) EV/Sales 1.90
P/S ratio (TTM) P/S ratio 0.92
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 12.32%
Revenue (TTM) Revenue $2.68b
EBIT (operating result TTM) EBIT $344.21m
Free Cash Flow (TTM) Free Cash Flow $101.30m
Cash position $78.35m
EPS (TTM) EPS $-0.68
P/E forward 479.39
P/S forward 0.89
EV/Sales forward 1.84
Short interest 1.14%
Show more

Is Amneal Pharmaceuticals, Inc. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Amneal Pharmaceuticals, Inc. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

Buy
75%
Hold
25%

Financial data from Amneal Pharmaceuticals, Inc. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2,680 2,680
12% 12%
100%
- Direct Costs 1,697 1,697
11% 11%
63%
983 983
16% 16%
37%
- Selling and Administrative Expenses 230 230
22% 22%
9%
- Research and Development Expense 183 183
14% 14%
7%
571 571
13% 13%
21%
- Depreciation and Amortization 227 227
3% 3%
8%
EBIT (Operating Income) EBIT 344 344
27% 27%
13%
Net Profit -184 -184
1,887% 1,887%
-7%

In millions USD.

Don't miss a Thing! We will send you all news about Amneal Pharmaceuticals, Inc. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amneal Pharmaceuticals, Inc. Class A Stock News

Neutral
Business Wire
7 days ago
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025.
Neutral
Business Wire
13 days ago
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved memantine/donepezil 14-10 mg and 28-10 mg extended-release capsules, which references Abbvie's NAMZARIC®, and Everolimus 2 mg, 3 mg and 5 mg extended-release capsules, which references Novartis' AFINITOR DISPERZ...
Neutral
Business Wire
2 months ago
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Participate at Upcoming Investor Conferences.
More Amneal Pharmaceuticals, Inc. Class A News

Company Profile

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Head office United States
CEO Chintu Patel
Employees 7,850
Founded 2002
Website www.amneal.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today